雅各臣科研製藥(02633.HK)與復星醫藥簽署在香港及澳門分銷2019冠狀病毒病疫苗意向書
格隆匯 8 月 27日丨雅各臣科研製藥(02633.HK)公告，公司與上海復星醫藥(集團)股份有限公司("復星醫藥"，於中華人民共和國註冊成立的股份有限公司，其股份於香港聯合交易所有限公司(股份代號：2196)及上海證券交易所上市(股票代碼：600196)，連同其附屬公司統稱"復星醫藥集團")的全資附屬公司復星實業(香港)有限公司("復星實業")於2020年8月27日訂立一份意向書，內容有關(其中包括)於中華人民共和國香港特別行政區("香港")及澳門特別行政區(("澳門"，連同香港，統稱"區域內")供銷潛在1仟萬劑針對2019冠狀病毒病的BioNTechBNT162在研疫苗("2019冠狀病毒病疫苗")("意向書")。
2019冠狀病毒病疫苗基於Biopharmaceutical New TechnologiesSE("BioNTechSE")專有的信使核糖核酸("mRNA")技術平台開發，該公司為於美利堅合眾國("美國")納斯達克上市(股份代號：BNTX)的領先德國生物技術公司。2019冠狀病毒病疫苗是用於預防2019冠狀病毒病感染的mRNA生物製劑，並已進展至臨牀研究三期。BioNTechSE已基於其專有的mRNA平台開發四款在研疫苗，其中兩款(即BNT162b1及BNT162b2)已取得美國食品藥品監督管理局(FoodandDrugAdministration)的快速通道認證。疫苗接種要求參與者在三角肌接受兩劑0.5毫升的BNT162b1或BNT162b2，前後相隔21日注射。
根據BioNTechSE發佈的公開資料，於美國的一期研究中，注射第二劑30微克BNT162b2後，於較年輕成年人(18至55歲)中引起的SARS-CoV-2中和幾何平均滴度是一組38例SARS-CoV-2康復者血清幾何平均滴度的2.8至3.8倍；而該在研疫苗於較年長成年人(65至85歲)中引起的SARS-CoV-2中和幾何平均滴度是同一組康復者血清中和幾何平均滴度的1.1至1.6倍，突顯其對兩個成人組別均有強免疫原性1。在所有人羣中，BNT162b2的使用耐受性良好，少於20%參與者出現輕微至中度發燒2。該等結果使BNT162b2在研疫苗獲選進入於2020年七月開始對多達30,000名參與者進行的關鍵第二╱三階段全球研究，其迄今已招募逾11,000名參與者，包括於SARS-CoV-2大規模傳播的地區3。
復星醫藥集團將致力與BioNTechSE協商，以於區域內供應1仟萬劑2019冠狀病毒病疫苗。根據意向書，公司及╱或其業務合作伙伴將就復星醫藥集團於區域內的2019冠狀病毒病疫苗的銷售、營銷及分銷提供所有相關的支援服務。預期該等服務將主要包括執行銷售及營銷計劃、提供上市後的藥物警戒及處理境內及境外物流，以及法規事務的技術及聯絡支援(統稱"業務合作")。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
